Ixazomib

Generic Name
Ixazomib
Brand Names
Ninlaro
Drug Type
Small Molecule
Chemical Formula
C14H19BCl2N2O4
CAS Number
1072833-77-2
Unique Ingredient Identifier
71050168A2
Background

Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...

Indication

Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Associated Conditions
Multiple Myeloma (MM)
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath